Donate

Adjuvant Radiotherapy Benefits Survival in Subsets of Men With Node-Positive Prostate Cancer

In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy)  enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]

Long-Term Survival Possible in Prostate Cancer With Bone Metastases

Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]

Enzalutamide (Xtandi) Improves The Quality of Life As Well As Extending Life In Men With Castrate Resistant Prostate Cancer

In clinical trials Enzalutamide (Xtandi) significantly increased the overall survival and radiographic progression-free survival of men when compared with placebo. The trial, called PREVAIL evaluated men who were asymptomatic and minimally symptomatic, chemotherapy-naive with metastatic castration-resistant prostate cancer. The researchers expanded the data analysis and evaluated the effect of Xtandi on the men’s health-related quality [...]

How Men Can Preserve Their Emotional Well Being When Fighting Advanced Prostate Cancer -Ideas For Interventions

In a study performed in the UK researchers explored how men with advanced prostate cancer support their personal well being. The study analyzed the practices used by five (5) men with advanced prostate cancer to maintain their emotional wellbeing. Information about the men’s individual practices was taken from face-to-face, semi-structured, in-depth interviews with the five [...]

Predicting A Minimal Response To Abiraterone In Men With Metastatic Castrate Resistant Prostate Cancer

We currently have several treatments for men with Metastatic Castration Resistant Prostate Cancer (mCRPC) that prolong survival. However, we don’t understand the optimum sequencing of these drugs. Personalized medicine is beginning to use genetic predictors to to help make treatment decisions so that expensive potentially toxic therapies can be avoided in men who have minimal [...]

More On The Efficacy Of Sipuleucel-T (Provenge) – It Works

Despite its approval five years ago sipuleucel-T (Provenge) remains one of the most controversial treatments available for men with castrate resistant metastatic prostate cancer (mCRPC). Provenge has its advocates (Full Disclosure- I am) and it has many detractors. The detractors argue that it doesn’t work and they hang their hat on the argument that it [...]

Lethal Advanced Prostate Cancer Has Inherently Heterogeneity And Can Spread From Other Metastatic Sites

We still have a lot to learn about how prostate cancer actually spreads, or metastasizes. Current theory holds that the primary tumor is probably most responsible for the development of distant metastases. In a new genomic analysis of tissue performed at the Johns Hopkins University using tissue from prostate cancer patients this paradigm has been [...]

Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer *

Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]

Detecting Prostate Cancer Cells in Blood Can Give An Early Warning of Treatment Failure and Shorten Clinical Trials

There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]

Is Cabazitaxel Before Docetaxel The Future Way To Go? *

Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. A study published online in Clinical Cancer Research, indicates that cabazitaxel might be more effective for some men than docetaxel. [...]

Go to Top